Fakultní nemocnice v Motole Fakultní nemocnice v Motole

přejdi na obsah | přejdi na menu | přejdi na vyhledávání

Publikace 2014

Zahraniční publikace s impact factorem:

1. Pavlík T, Májek O, Büchler T, Vyzula R, Petera J, Ryska M, Ryška A, Cibula D, Babjuk M, Abrahámová J, Vorlíček J, Mužík J, Dušek L.Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008. Cancer Epidemiol. 2014 Feb;38(1):28-34. doi: 10.1016/j.canep.2013.11.002.

IF 2.558

 

2. Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, Mariappan P, Palou Redorta J, Stenzl A, van Velthoven R, Zaak D. Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations.

Eur Urol. 2014 Jul 4. pii: S0302-2838(14)00611-3. doi: 10.1016/j.eururo.2014.06.037

IF 12.480

 

3. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Holmäng S, Babjuk M, Fajkovic H, Seitz C, Klatte T, Pycha A, Bachmann A, Scherr DS, Shariat SF. Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder. Eur Urol. 2014 Jan;65(1):201-9. doi: 10.1016/j.eururo.2013.08.034.

IF 12.480

 

4. Colombel M, Heidenreich A, Martínez-Piñeiro L, Babjuk M, Korneyev I, Surcel C, Yakovlev P, Colombo R, Radziszewski P, Witjes F, Schipper R, Mulders P, Witjes WP. Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trial. Eur Urol. 2014 Mar;65(3):509-11. doi: 10.1016/j.eururo.2013.10.056.

IF 12.480

 

5. Klatte T, Xylinas E, Rieken M, Kluth LA, Rouprêt M, Pycha A, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, Scherr DS, Shariat SF. Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. J Urol. 2014 May;191(5):1238-43. doi: 10.1016/j.juro.2013.11.106.

IF 3.753

 

6. Soukup V, Dušková J, Pešl M, Čapoun O, Feherová Z, Zámečník L, Hanuš T, Babjuk M. The prognostic value of T1 bladder cancer substaging: a single institution retrospective study. Urol Int. 2014;92(2):150-6. doi: 10.1159/000355358.

IF 1.151

 

7. Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, Shariat SF. Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. Urol Oncol. 2014 Jul;32(5):625-30. doi: 10.1016/j.urolonc.2013.11.010.

IF 3.363

 

8. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Babjuk M, Bachmann A, Scherr DS, Shariat SF.: Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol Oncol. 2014 Jan;32(1):49.e7-14. doi: 10.1016/j.urolonc.2013.07.006.

IF 3.363

 

9. Aziz A, Shariat SF, Roghmann F, Brookman-May S, Stief CG, Rink M, Chun FK, Fisch M, Novotny V, Froehner M, Wirth MP, Schnabel MJ, Fritsche HM, Burger M, Pycha A, Brisuda A, Babjuk M, Vallo S, Haferkamp A, Roigas J, Noldus J, Stredele R, Volkmer B, Bastian PJ, Xylinas E, May M.: Prediction of Cancer-Specific Survival After Radical Cystectomy in pT4a Urothelial Carcinoma of the Bladder - Development of a Tool for Clinical Decision-making. BJU Int. 2014 Nov 10. doi: 10.1111/bju.12984.

IF 3.130

 

10. May M, Aziz A, Brookman-May S, Roghmann F, Noldus J, Rink M, Chun F, Fisch M, Novotny V, Wirth M, Mayr R, Pycha A, Brisuda A, Volkmer B, Stredele R, Dechet C, Vallo S, Haferkamp A, Schnabel M, Denzinger S, Roigas J, Stief CG, Gilfrich C, Bastian PJ, Engel JB, Burger M, Fritsche HM.: Prognostic impact of infiltration of the vagina and/or uterus in women undergoing anterior pelvic exenteration for urothelial carcinoma of the bladder: results of a contemporary multicentre series. World J Urol. 2014 May 10.

IF 3.423

 

11. Duskova K, Vesely S. Prostate Specific Antigen. Current clinical application and future prospects.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Oct 2. doi: 10.5507/bp.2014.046.

IF 1.661

 

12. Hrbáček J, Macek P, Ali-El-Dein B, Thalmann GN, Stenzl A, Babjuk M, Shaaban AA, Gakis G.: Treatment and Outcomes of Urethral Recurrence of Urinary Bladder Cancer in Women after Radical Cystectomy and Orthotopic Neobladder: A Series of 12 Cases. Urol Int. 2014 Aug 21

IF 1.151

 

13. Chocholatý M, Jáchymová M, Schmidt M, Havlová K, Křepelová A, Zima T, Babjuk M, Kalousová M. Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer. Tumour Biol. 2014 Nov 19.

IF 2.840

 

14. Vesely S, Jarolim L, Duskova K, Schmidt M, Dusek P, Babjuk M. The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy. BMC Urol. 2014 Oct 2;14:79. doi: 10.1186/1471-2490-14-79.

IF 1.940

 

15. Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzàlez-Porta M, Wozniak MB, Bourgey M, Harnden P, Egevad L, Jackson SM, Karimzadeh M, Arseneault M, Lepage P, How-Kit A, Daunay A, Renault V, Blanché H, Tubacher E, Sehmoun J, Viksna J, Celms E, Opmanis M, Zarins A, Vasudev NS, Seywright M, Abedi-Ardekani B, Carreira C, Selby PJ, Cartledge JJ, Byrnes G, Zavadil J, Su J, Holcatova I, Brisuda A, Zaridze D, Moukeria A, Foretova L, Navratilova M, Mates D, Jinga V, Artemov A, Nedoluzhko A, Mazur A, Rastorguev S, Boulygina E, Heath S, Gut M, Bihoreau MT, Lechner D, Foglio M, Gut IG, Skryabin K, Prokhortchouk E, Cambon-Thomsen A, Rung J, Bourque G, Brennan P, Tost J, Banks RE, Brazma A, Lathrop GM.: Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun. 2014 Oct 29;5:5135. doi: 10.1038/ncomms6135.

IF 10.742

 

Zahraniční publikace bez impact factoru:

1. Poletajew S, Braticevici B, Brisuda A, Cauni V, Grygorenko V, Lesnyak M-Z, et al. Timing of radical cystectomy in Central Europe – multicenter study on factors influencing the time from diagnosis to radical treatment of bladder cancer patients. Cent European J Urol doi: 10.5173/ceju.2014.444

 

2. May M, Brookman-May S, Burger M, Gilfrich C, Fritsche HM, Rink M, Chun F, Fisch M, Roghmann F, Noldus J, Mayr R, Pycha A, Novotny V, Wirth M, Vallo S, Haferkamp A, Roigas J, Brisuda A, Stredele R, Volkmer B, Dechet C, Schnabel M, Denzinger S, Stief CG, Bastian PJ, Aziz A.: Concomitant seminal vesicle invasion in pT4a urothelial carcinoma of the bladder with contiguous prostatic infiltration is an adverse prognosticator for cancer-specific survival after radical cystectomy.

Ann Surg Oncol. 2014 Nov;21(12):4034-40. doi: 10.1245/s10434-014-3827-y. Epub 2014 Jun 4.

 

3. Hrbáček J. URS versus ESWL: another contribution to the never-ending debate.

Cent European J Urol. 2014;66(4):463-4. doi: 10.5173/ceju.2013.04.art20

 

Domácí publikace:

1. Dusek L, Muzik J, Maluskova D, Májek O, Pavlík T, Koptíková J, Melichar B, Büchler T, Fínek J, Cibula D, Babjuk M, Svoboda M, Vyzula R, Ryska A, Ryska M, Petera J, Abrahámová J. Cancer Incidence and Mortality in the Czech Republic. Klin Onkol. 2014 Winter;27(6):406-423. 

 

2. Jarolím L.: Screening karcinomu prostaty. In: www.farmakoterpie.cz, Karcinom prostaty - monografie, 2014

 

3. Babjuk M.: Aktuální pohled na diagnostiku a léčbu karcinomu prostaty v ČR z pohledu urologa. In. www.farmakoterapie.cz, Karcinom prostaty – monografie, 2014

 

4. Jarolím L. Místo radikální prostatektomie v léčbě vysoce rizikového karcinomu prostaty. In: Postgraduální medicína 2014, 16, č.8

 

5. Kříž J., Rejchrt M. Autonomní dysreflexie – závažná komplikace u pacientů po poranění míchy. Cesk Slov Neurol N 2014, 77/110(2): 168-173

 

6. Cernei, N.ab, Heger, Z.ab, Veselý, Š.c, Zítka, O.ab, Adam, V.ab, Kizek, R.: Chromatografická charakterizace aminokyselinových profilů vzorků moči pacientů s karcinomem prostaty. Klin Biochem Metab Vol. 22, Issue 4, 2014, Pages 196-202

 

 

 

 

 

 

Partneři

© Fakultní nemocnice v Motole 2012. Všechna práva vyhrazena.

Odebírejte novinky (RSS)

Mapa webu

developed by MEDIA FACTORY